5HC Wainwright & Co. Maintains Buy on Actinium Pharma, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Actinium Pharma (AMEX:ATNM) but lowers the price target from $50 to $4.

August 06, 2024 | 6:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Actinium Pharma but lowers the price target from $50 to $4.
The significant reduction in the price target from $50 to $4, despite maintaining a Buy rating, suggests a major reassessment of the company's valuation. This could lead to short-term negative sentiment and downward pressure on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100